Nachrichten zur Vertex Pharmaceuticals Inc. Aktie

Vertex Pharmaceuticals: Neues Kursziel

San Francisco (www.aktiencheck.de) - Rating-Update: Die Analysten von Wells Fargo Advisors stufen die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

Vertex Pharmaceuticals: Fortschritte in der Pipeline, M&A-Aktivitäten und finanzielle Stärke im Fokus - Aktienanalyse

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Argus Research: Jasper Hellweg, Analyst von Argus Research, erhöht in einer aktuellen Aktienanalyse sein…

Analyst Report: Vertex Pharmaceuticals, Inc.

…

Cystic Fibrosis Therapeutics Global Strategic Business Report 2023-2030 Featuring Key Players - AbbVie, Galapagos, Genentech, Gilead Sciences, Novartis, and Vertex Pharmaceuticals

Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Therapeutics - Global Strategic Business Report" report has…

Vertex Pharmaceuticals: Kursziel gekappt

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten vom Investmenthaus RBC Capital Markets bestätigen das "sector-perform"-Rating für die Aktie von Vertex Pharmaceuticals Inc.…

Vertex Pharmaceuticals: VX-548 im Fokus - Aktienanalyse

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von BMO Capital Markets: Die Analysten von BMO Capital Markets stufen die Aktie von Vertex Pharmaceuticals…

Is It Too Late to Buy Vertex Pharmaceuticals Stock?

Shares of the growing biotech company have doubled in three years.…

Is It Too Late to Buy Vertex Pharmaceuticals Stock? @themotleyfool #stocks $VRTX

Shares of the growing biotech company have doubled in three years.…

3 High-Flying Stocks That Could Soar Even More

The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.…

ADDvise receives order worth USD 1.4 million

Axelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and…

Vertex Pharmaceuticals executive sells shares worth over $13k By Investing.com

Vertex Pharmaceuticals executive sells shares worth over $13k…

Vertex Is Writing A New Playbook For Pharma R&D. And It’s Working.

Vertex Pharmaceuticals (NDAQ: VRTX) path to becoming a top 20 pharma company with over a $100 billion market cap has…

Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy

The biotechs shares dropped following its latest quarterly update, but that shouldnt matter to long-term investors.…

Vertex Pharmaceuticals: Höheres Kursziel

Boston, MA (www.aktiencheck.de) - Rating-Update: Die Analysten von Leerink Partners wiederholen ihre Empfehlung "outperform" für die Aktie von Vertex Pharmaceuticals Inc.…

Vertex Pharmaceuticals: Kursziel hochgesetzt

Toronto (www.aktiencheck.de) - Rating-Update: Im Rahmen seiner Einschätzung bleibt Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bei seiner "sector-perform"-Bewertung für…

Vertex Pharmaceuticals: Kurszielanhebung

Minneapolis (www.aktiencheck.de) - Rating-Update: Die Analysten von Piper Sandler bewerten die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807,…

5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip @themotleyfool #stocks $VRTX

New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy…

5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip

New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy…

Futures Mixed As Disney Dives On Revenue Miss

Key earnings movers include Datadog, Palantir and Vertex Pharmaceuticals.…

Vertex Pharmaceuticals, Inc. (VRTX) Q1 2024 Earnings Call Transcript

…

Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript

VRTX earnings call for the period ending March 31, 2024.…

Vertex Stock Flat On Reiterated Outlook Despite First-Quarter Beat

Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts, but shares were little moved on the reiterated guidance.…

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…

Vertex Pharmaceuticals: Kurszielsenkung

Charlotte (www.aktiencheck.de) - Rating-Update: Die Analysten von BofA Securities bewerten die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol:…

Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? @themotleyfool #stocks $VRTX $CRSP $ALPN

Vertex is broadening its portfolio.…

Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?

Vertex is broadening its portfolio.…

If Youd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Heres How Much Youd Have Today

Could Vertexs growth story continue?…

Vertex Pharmaceuticals: Hochstufung

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Evercore ISI stufen die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807,…

Vertex Pharmaceuticals: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von H.C. Wainwright & Co. bewerten die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN:…

Could This Stock Be the Next Biotech Buyout? @themotleyfool #stocks $VERA $VRTX $ALPN

Vertex Pharmaceuticals $4.9 billion purchase of Alpine Immune Sciences probably wont be the last acquisition of a company focused on…

Could This Stock Be the Next Biotech Buyout?

Vertex Pharmaceuticals $4.9 billion purchase of Alpine Immune Sciences probably wont be the last acquisition of a company focused on…

Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse

…

What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences

…

Jim Cramer shares his thoughts on Nike, Vertex Pharmaceuticals, CarMax, Airbnb, Visa and Mastercard

During the CNBC Investing Clubs Morning Meeting, Jim Cramer weighed in on the stock moves in Nike, Vertex Pharma and…

Vertex Pharmaceuticals: Buy, Sell, or Hold? @themotleyfool #stocks $VRTX

The stock hasnt made for a great buy this year, but is Vertex worth investing in for the long run?…

Vertex Pharmaceuticals: Buy, Sell, or Hold?

The stock hasnt made for a great buy this year, but is Vertex worth investing in for the long run?…

Vertex Pharmaceuticals: Übernahme von Alpine Immune Sciences - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Vertex Pharmaceuticals Inc.…

Milliarden-Deal! Ausgerechnet Vertex schlägt zu

Große Pharma- und Biotech-Unternehmen sind weiter auf der Suche nach aussichtsreichen Substanzen, um ihre Produktpipeline zu stärken. Der unangefochtene Weltmarktführer…

Milliarden-Deal! Ausgerechnet Vertex schlägt zu

Große Pharma- und Biotech-Unternehmen sind weiter auf der Suche nach aussichtsreichen Substanzen, um ihre Produktpipeline zu stärken. Der unangefochtene Weltmarktführer…

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

…

Übernahme: Vertex Pharmaceuticals erwirbt Alpine Immune für Milliardensumme

Das biopharmazeutische Unternehmen will die Biotechfirma für rund 4,9 Milliarden Dollar übernehmen. Die Aktien von Alpine legten nachbörslich 36 Prozent…

Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion

With the acquisition, Vertex will add Alpines portfolio of protein-based immunotherapies to treat autoimmune and inflammatory diseases.…

Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln

Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the…

Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion By Reuters

Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion…

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in…

Vertex Pharmaceuticals: Ein führender Schmerzmediziner "bemerkenswert negativ" zu VX-548 - Aktienanalyse

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die Analysten vom Investmenthaus RBC Capital Markets trauen der Aktie von Vertex…

Vertex Pharmaceuticals executive sells shares worth over $100k By Investing.com

Vertex Pharmaceuticals executive sells shares worth over $100k…

Vertex (VRTX) Continues to Diversify Beyond CF Franchise

While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of…

Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development

Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this…

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

…